References
- Drug delivery in cancer – technologies, markets & companies. (2019). www.researchandmarkets.com/reports/4748166/drug-delivery-in-cancer-technologies-markets?utm_source=BW&utm_medium=PressRelease&utm_code=5trr5w&utm_campaign=1282967+-+Cancer+Drug+Delivery+Research+Report+2019%3a+Focus+on+Technologies%2c+Markets+%26+Companies+-+Updated+Estimates+to+2029&utm_exec=chdo54prd
- Kala pharmaceuticals reports inducement grant under Nasdaq listing rule 5635(C)(4). (2019). http://investors.kalarx.com/news-releases/news-release-details/kala-pharmaceuticals-reports-inducement-grant-under-nasdaq-8
- Ironwood pharmaceuticals and alnylam pharmaceuticals enter U.S. GI disease education and promotional agreement for Alnylam’s Givosiran in acute hepatic porphyria (AHP). (2019). https://investor.ironwoodpharma.com/press-releases/press-release-details/2019/Ironwood-Pharmaceuticals-and-Alnylam-Pharmaceuticals-Enter-US-GI-Disease-Education-and-Promotional-Agreement-for-Alnylams-Givosiran-in-Acute-Hepatic-Porphyria-AHP/default.aspx
- Arrowhead collaborator Janssen begins REEF-1 Phase IIb combination study in patients with chronic hepatitis B infection. (2019). http://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-collaborator-janssen-begins-reef-1-phase-2b
- Arrowhead pharmaceuticals doses first patient in SEQUOIA Phase II/III study of ARO-AAT for treatment of alpha-1 liver disease. (2019). http://ir.arrowheadpharma.com/node/14736/pdf
- Long-acting injectable antipsychotic using MedinCell’s technology receives FDA IND clearance to initiate clinical activities. (2019). www.medincell.com/wp-content/uploads/2019/08/2019_08_26_MEDCL_PR_mdcTJK_IND-clearance_ENG_final.pdf
- Imbrium Therapeutics L.P. and Spinethera announce issuance of U.S. patent covering composition of matter protection forSX600, a non-opioid product in development for epidural steroid injection for the treatment of low back pain. (2019). www.imbriumthera.com/news/imbrium-therapeutics-l-p-and-spinethera-announce-issuance-of-u-s-patent-covering-composition-of-matter-protection-for-sx600-a-non-opioid-product-in-development-for-epidural-steroid-injection-for-th/
- Bioasis announces registration and grant notice of patent application in China relating to xB3 platform technology for the delivery of therapeutic agents across the blood–brain barrier. (2019). www.biospace.com/article/releases/bioasis-announces-registration-and-grant-notice-of-patent-application-in-china-relating-to-xb3-platform-technology-for-the-delivery-of-therapeutic-agents-across-the-blood-brain-barrier/
- Computational model of coating and tissue morphology determinants of balloon based drug retention and tissue dosing suggest a new paradigm for accelerated treatment optimization: CBSET data published in Journal of Controlled Release. (2019). http://cbset.org/press-release-computational-model-coating-tisseu-morphology-determinants-balloon-absed-drug-retention/
- Singh AP , BiswasA , ShuklaA , MaitiP. Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. SignalTransduct. Target. Ther.4, 33–54 (2019).
- Mansoor S , KondiahPPD , ChoonaraYE , PillayV. Polymer-based nanoparticle strategies for insulin delivery. Polymers (Basel)11(9), 1380–1407 (2019).
- Onaciu A , MunteanuRA , MoldovanAI , MoldovanCS , Berindan-NeagoeI. Hydrogels based drug delivery synthesis, characterization and administration. Pharmaceutics11(9), 432–456 (2019).